Clinical Trial Update: A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating immune responses to influenza and pneumococcal vaccines in rheumatoid arthritis patients treated with CP-690,550 (tofacitinib) or pla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CP-690,550 (tofacitinib) (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2013-03-29